OBJECTIVES: People with vascular dementia (VaD) are frequently prescribed atypical antipsychotics to treat behavioural and psychological symptoms, but there is an alarming lack of evidence regarding their safety or efficacy in VaD. This study sought to identify the mortality risk associated with the most commonly prescribed atypical antipsychotics in people with VaD compared with people not exposed to these drugs. METHODS: A clinical cohort study of 1531 people with VaD performed using anonymised versions of full electronic health records from the Clinical Record Interactive Search application at the South London and Maudsley NHS Foundation Trust. Patients were identified from 2007 to 2010, of whom 337 were exposed to quetiapine, risperidone or olanzapine. The main outcome measure was mortality. RESULTS: Patients exposed to atypical antipsychotics were not at increased risk of mortality [hazard ratio (HR) 1.05, 95% confidence interval (CI): 0.87-1.26]. Exposure to risperidone did not result in an increased risk of mortality (HR = 0.85; 95% CI: 0.59-1.24), and patients exposed to quetiapine had a non-significant numerical increase in mortality risk (HR = 1.14; 95% CI: 0.93-1.39; p-value = 0.20) compared with untreated patients. Too few patients were exposed to olanzapine alone to provide reliable results. CONCLUSIONS: The absence of a significant increase in mortality risk associated with atypical antipsychotics in people with VaD indicates that a clinical trial of antipsychotics focussing on the treatment of aggression and agitation in this patient group will be justified and feasible following further consideration of possible confounders, which will be critical to determine the role of antipsychotics in treatment of VaD.
OBJECTIVES: People with vascular dementia (VaD) are frequently prescribed atypical antipsychotics to treat behavioural and psychological symptoms, but there is an alarming lack of evidence regarding their safety or efficacy in VaD. This study sought to identify the mortality risk associated with the most commonly prescribed atypical antipsychotics in people with VaD compared with people not exposed to these drugs. METHODS: A clinical cohort study of 1531 people with VaD performed using anonymised versions of full electronic health records from the Clinical Record Interactive Search application at the South London and Maudsley NHS Foundation Trust. Patients were identified from 2007 to 2010, of whom 337 were exposed to quetiapine, risperidone or olanzapine. The main outcome measure was mortality. RESULTS: Patients exposed to atypical antipsychotics were not at increased risk of mortality [hazard ratio (HR) 1.05, 95% confidence interval (CI): 0.87-1.26]. Exposure to risperidone did not result in an increased risk of mortality (HR = 0.85; 95% CI: 0.59-1.24), and patients exposed to quetiapine had a non-significant numerical increase in mortality risk (HR = 1.14; 95% CI: 0.93-1.39; p-value = 0.20) compared with untreated patients. Too few patients were exposed to olanzapine alone to provide reliable results. CONCLUSIONS: The absence of a significant increase in mortality risk associated with atypical antipsychotics in people with VaD indicates that a clinical trial of antipsychotics focussing on the treatment of aggression and agitation in this patient group will be justified and feasible following further consideration of possible confounders, which will be critical to determine the role of antipsychotics in treatment of VaD.
Authors: Clare L Taylor; Robert Stewart; Jack Ogden; Matthew Broadbent; Dharmintra Pasupathy; Louise M Howard Journal: BMC Psychiatry Date: 2015-04-17 Impact factor: 3.630
Authors: Karolina Magda Bogdanowicz; Robert Stewart; Chin-Kuo Chang; Johnny Downs; Mizanur Khondoker; Hitesh Shetty; John Strang; Richard Derek Hayes Journal: Drug Alcohol Depend Date: 2016-05-06 Impact factor: 4.492
Authors: Martin Knapp; Kia-Chong Chua; Matthew Broadbent; Chin-Kuo Chang; Jose-Luis Fernandez; Dominique Milea; Renee Romeo; Simon Lovestone; Michael Spencer; Gwilym Thompson; Robert Stewart; Richard D Hayes Journal: BMJ Open Date: 2016-11-18 Impact factor: 2.692
Authors: Jon Brännström; Gustaf Boström; Erik Rosendahl; Peter Nordström; Håkan Littbrand; Hugo Lövheim; Yngve Gustafson Journal: BMC Pharmacol Toxicol Date: 2017-05-25 Impact factor: 2.483
Authors: Gayan Perera; Matthew Broadbent; Felicity Callard; Chin-Kuo Chang; Johnny Downs; Rina Dutta; Andrea Fernandes; Richard D Hayes; Max Henderson; Richard Jackson; Amelia Jewell; Giouliana Kadra; Ryan Little; Megan Pritchard; Hitesh Shetty; Alex Tulloch; Robert Stewart Journal: BMJ Open Date: 2016-03-01 Impact factor: 2.692